3
|
Fukai R, Ogo N, Ichida T, Yamane M, Sawada JI, Miyoshi N, Murakami H, Asai A. Design, synthesis, and evaluation of a novel prodrug, a S-trityl- l-cysteine derivative targeting kinesin spindle protein. Eur J Med Chem 2021; 215:113288. [PMID: 33640763 DOI: 10.1016/j.ejmech.2021.113288] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Revised: 01/30/2021] [Accepted: 02/03/2021] [Indexed: 11/29/2022]
Abstract
Kinesin spindle protein (KSP) is expressed only in cells undergoing cell division, and hence represents an attractive target for the treatment of cancer. Several KSP inhibitors have been developed and undergone clinical trial, but their clinical use is limited by their toxicity to rapidly proliferating non-cancerous cells. To create new KSP inhibitors that are highly selective for cancer cells, we optimized the amino acid moiety of S-trityl-l-cysteine (STLC) derivative 1 using in silico modeling. Molecular docking and molecular dynamics simulation were performed to investigate the binding mode of 1 with KSP. Consistent with the structure activity relationship studies, we found that a cysteine amino moiety plays an important role in stabilizing the interaction. Based on these findings and the structure of GSH, a substrate of γ-glutamyltransferase (GGT), we designed and synthesized the prodrug N-γ-glutamylated STLC derivative 9, which could be hydrolyzed by GGT to produce 1. The KSP ATPase inhibitory activity of 9 was lower than that of 1, and LC-MS analysis indicated that 9 was converted to 1 only in the presence of GGT in vitro. In addition, the cytotoxic activity of 9 was significantly attenuated in GGT-knockdown A549 cells. Since GGT is overexpressed on the cell membrane of various cancer cells, these results suggest that compound 9 could be a promising prodrug that selectively inhibits the proliferation of GGT-expressing cancer cells.
Collapse
Affiliation(s)
- Ryota Fukai
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan
| | - Naohisa Ogo
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan.
| | - Taiki Ichida
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan
| | - Masayoshi Yamane
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan
| | - Jun-Ichi Sawada
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan
| | - Nao Miyoshi
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan
| | - Hisashi Murakami
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan
| | - Akira Asai
- Center for Drug Discovery, Graduate Division of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Suruga-ku, Shizuoka, 422-8526, Japan.
| |
Collapse
|
4
|
Łomzik M, Hanif M, Budniok A, Błauż A, Makal A, Tchoń DM, Leśniewska B, Tong KKH, Movassaghi S, Söhnel T, Jamieson SMF, Zafar A, Reynisson J, Rychlik B, Hartinger CG, Plażuk D. Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands. Inorg Chem 2020; 59:14879-14890. [PMID: 33003697 PMCID: PMC7584371 DOI: 10.1021/acs.inorgchem.0c00957] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Ispinesib is a potent inhibitor of kinesin spindle protein (KSP), which has been identified as a promising target for antimitotic anticancer drugs. Herein, we report the synthesis of half-sandwich complexes of Ru, Os, Rh, and Ir bearing the ispinesib-derived N,N-bidentate ligands (R)- and (S)-2-(1-amino-2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one and studies on their chemical and biological properties. Using the enantiomerically pure (R)- and (S)-forms of the ligand, depending on the organometallic moiety, either the SM,R or RM,S diastereomers, respectively, were observed in the molecular structures of the Ru- and Os(cym) (cym = η6-p-cymene) compounds, whereas the RM,R or SM,S diastereomers were found for the Rh- and Ir(Cp*) (Cp* = η5-pentamethylcyclopentadienyl) derivatives. However, density functional theory (DFT) calculations suggest that the energy difference between the diastereomers is very small, and therefore a mixture of both will be present in solution. The organometallics exhibited varying antiproliferative activity in a series of human cancer cell lines, with the complexes featuring the (R)-enantiomer of the ligand being more potent than the (S)-configured counterparts. Notably, the Rh and Ir complexes demonstrated high KSP inhibitory activity, even at 1 nM concentration, which was independent of the chirality of the ligand, whereas the Ru and especially the Os derivatives were much less active.
Collapse
Affiliation(s)
- Michał Łomzik
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, ul. Tamka 12, 91-403 Łódź, Poland
| | - Muhammad Hanif
- School of Chemical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Aleksandra Budniok
- Cytometry Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, ul. Pomorska 141/143, 90-236 Łódź, Poland
| | - Andrzej Błauż
- Cytometry Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, ul. Pomorska 141/143, 90-236 Łódź, Poland
| | - Anna Makal
- Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, ul. Żwirki i Wigury 101, 02-089 Warszawa, Poland
| | - Daniel M Tchoń
- Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, ul. Żwirki i Wigury 101, 02-089 Warszawa, Poland
| | - Barbara Leśniewska
- Faculty of Chemistry, University of Białystok, ul. K. Ciołkowskiego 1 K, 15-245 Białystok, Poland
| | - Kelvin K H Tong
- School of Chemical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Sanam Movassaghi
- School of Chemical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Tilo Söhnel
- School of Chemical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Stephen M F Jamieson
- Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Ayesha Zafar
- School of Chemical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Jóhannes Reynisson
- School of Pharmacy and Bioengineering, Keele University, Hornbeam Building, Staffordshire ST5 5BG, United Kingdom
| | - Błażej Rychlik
- Cytometry Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, ul. Pomorska 141/143, 90-236 Łódź, Poland
| | - Christian G Hartinger
- School of Chemical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
| | - Damian Plażuk
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, ul. Tamka 12, 91-403 Łódź, Poland
| |
Collapse
|
17
|
Qian X, McDonald A, Zhou HJ, Adams ND, Parrish CA, Duffy KJ, Fitch DM, Tedesco R, Ashcraft LW, Yao B, Jiang H, Huang JK, Marin MV, Aroyan CE, Wang J, Ahmed S, Burgess JL, Chaudhari AM, Donatelli CA, Darcy MG, Ridgers LH, Newlander KA, Schmidt SJ, Chai D, Colón M, Zimmerman MN, Lad L, Sakowicz R, Schauer S, Belmont L, Baliga R, Pierce DW, Finer JT, Wang Z, Morgan BP, Morgans DJ, Auger KR, Sung CM, Carson JD, Luo L, Hugger ED, Copeland RA, Sutton D, Elliott JD, Jackson JR, Wood KW, Dhanak D, Bergnes G, Knight SD. Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295. ACS Med Chem Lett 2010; 1:30-4. [PMID: 24900171 DOI: 10.1021/ml900018m] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2009] [Accepted: 01/04/2010] [Indexed: 11/29/2022] Open
Abstract
Inhibition of mitotic kinesins represents a novel approach for the discovery of a new generation of anti-mitotic cancer chemotherapeutics. We report here the discovery of the first potent and selective inhibitor of centromere-associated protein E (CENP-E) 3-chloro-N-{(1S)-2-[(N,N-dimethylglycyl)amino]-1-[(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)methyl]ethyl}-4-[(1-methylethyl)oxy]benzamide (GSK923295; 1), starting from a high-throughput screening hit, 3-chloro-4-isopropoxybenzoic acid 2. Compound 1 has demonstrated broad antitumor activity in vivo and is currently in human clinical trials.
Collapse
Affiliation(s)
- Xiangping Qian
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Andrew McDonald
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Han-Jie Zhou
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Nicholas D. Adams
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Cynthia A. Parrish
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Kevin J. Duffy
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Duke M. Fitch
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Rosanna Tedesco
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Luke W. Ashcraft
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Bing Yao
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Hong Jiang
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Jennifer K. Huang
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Melchor V. Marin
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Carrie E. Aroyan
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Jianchao Wang
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Seyed Ahmed
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Joelle L. Burgess
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Amita M. Chaudhari
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Carla A. Donatelli
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Michael G. Darcy
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Lance H. Ridgers
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Ken A. Newlander
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Stanley J. Schmidt
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Deping Chai
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Mariela Colón
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Michael N. Zimmerman
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Latesh Lad
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Roman Sakowicz
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Stephen Schauer
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Lisa Belmont
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Ramesh Baliga
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Daniel W. Pierce
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Jeffrey T. Finer
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Zhengping Wang
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Bradley P. Morgan
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - David J. Morgans
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Kurt R. Auger
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Chiu-Mei Sung
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Jeff D. Carson
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Lusong Luo
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Erin D. Hugger
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Robert A. Copeland
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - David Sutton
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - John D. Elliott
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Jeffrey R. Jackson
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Kenneth W. Wood
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Dashyant Dhanak
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Gustave Bergnes
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| | - Steven D. Knight
- Cytokinetics, Inc., 280 E Grand Avenue, South San Francisco, California 94080
- Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426
| |
Collapse
|